Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch
This article was originally published in The Pink Sheet Daily
Amgen executives laid out the case for the heart failure candidate ivabradine, which will serve as a foundation for the launch of the company’s highly anticipated PCSK9 inhibitor, during a presentation at AHA. The company also presented the first 52-week data on evolocumab.
You may also be interested in...
In shifting away from specific targets and non-statin add-on therapies, new ACC/AHA cholesterol guidelines support treatment of people at relatively low risk for events and more intensive therapy for those at higher risk.
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.